BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 27367142)

  • 1. Targeted therapies in thyroid cancer: an extensive review of the literature.
    Bikas A; Vachhani S; Jensen K; Vasko V; Burman KD
    Expert Rev Clin Pharmacol; 2016 Oct; 9(10):1299-1313. PubMed ID: 27367142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lenvatinib: Role in thyroid cancer and other solid tumors.
    Cabanillas ME; Habra MA
    Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Targeted Therapies of Aggressive Thyroid Cancer.
    Ferrari SM; Fallahi P; Politti U; Materazzi G; Baldini E; Ulisse S; Miccoli P; Antonelli A
    Front Endocrinol (Lausanne); 2015; 6():176. PubMed ID: 26635725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thyroid Cancers: From Surgery to Current and Future Systemic Therapies through Their Molecular Identities.
    Lorusso L; Cappagli V; Valerio L; Giani C; Viola D; Puleo L; Gambale C; Minaldi E; Campopiano MC; Matrone A; Bottici V; Agate L; Molinaro E; Elisei R
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33803747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of advanced thyroid cancer with targeted therapies: ten years of experience.
    Viola D; Valerio L; Molinaro E; Agate L; Bottici V; Biagini A; Lorusso L; Cappagli V; Pieruzzi L; Giani C; Sabini E; Passannati P; Puleo L; Matrone A; Pontillo-Contillo B; Battaglia V; Mazzeo S; Vitti P; Elisei R
    Endocr Relat Cancer; 2016 Apr; 23(4):R185-205. PubMed ID: 27207700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Targeted Therapies for Metastatic Thyroid Cancer-A Comprehensive Review.
    Al-Jundi M; Thakur S; Gubbi S; Klubo-Gwiezdzinska J
    Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32751138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted Therapy in Thyroid Cancer: State of the Art.
    Valerio L; Pieruzzi L; Giani C; Agate L; Bottici V; Lorusso L; Cappagli V; Puleo L; Matrone A; Viola D; Romei C; Ciampi R; Molinaro E; Elisei R
    Clin Oncol (R Coll Radiol); 2017 May; 29(5):316-324. PubMed ID: 28318881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular basis and targeted therapy in thyroid cancer: Progress and opportunities.
    Zhang L; Feng Q; Wang J; Tan Z; Li Q; Ge M
    Biochim Biophys Acta Rev Cancer; 2023 Jul; 1878(4):188928. PubMed ID: 37257629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Era of Advances in Systemic Therapies for Advanced Thyroid Cancer.
    Yun KM; Cohen EEW
    JCO Oncol Pract; 2024 Mar; ():OP2300747. PubMed ID: 38452309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in pharmacotherapy for advanced thyroid cancer of follicular origin (PTC, FTC). New approved drugs and future therapies.
    Elia G; Ferrari SM; Ragusa F; Paparo SR; Mazzi V; Ulisse S; Benvenga S; Antonelli A; Fallahi P
    Expert Opin Pharmacother; 2022 Apr; 23(5):599-610. PubMed ID: 35038965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tyrosine kinase inhibitors rechallenge in solid tumors: a review of literature and a case description with lenvatinib in thyroid cancer.
    Felicetti F; Nervo A; Piovesan A; Berardelli R; Marchisio F; Gallo M; Arvat E
    Expert Rev Anticancer Ther; 2017 Dec; 17(12):1093-1098. PubMed ID: 28988510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
    Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
    Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Managing tyrosine kinase inhibitors side effects in thyroid cancer.
    Krajewska J; Paliczka-Cieslik E; Jarzab B
    Expert Rev Endocrinol Metab; 2017 Mar; 12(2):117-127. PubMed ID: 30063430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thyroid Gland Malignancies.
    Cabanillas ME; Dadu R; Hu MI; Lu C; Gunn GB; Grubbs EG; Lai SY; Williams MD
    Hematol Oncol Clin North Am; 2015 Dec; 29(6):1123-43. PubMed ID: 26568552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perspectives on the Treatment of Advanced Thyroid Cancer: Approved Therapies, Resistance Mechanisms, and Future Directions.
    Porter A; Wong DJ
    Front Oncol; 2020; 10():592202. PubMed ID: 33569345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel targeted therapies and immunotherapy for advanced thyroid cancers.
    Naoum GE; Morkos M; Kim B; Arafat W
    Mol Cancer; 2018 Feb; 17(1):51. PubMed ID: 29455653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical, safety, and economic evidence in radioactive iodine-refractory differentiated thyroid cancer: a systematic literature review.
    Anderson RT; Linnehan JE; Tongbram V; Keating K; Wirth LJ
    Thyroid; 2013 Apr; 23(4):392-407. PubMed ID: 23294230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in small molecule therapy for treating metastatic thyroid cancer.
    Krajewska J; Gawlik T; Jarzab B
    Expert Opin Pharmacother; 2017 Aug; 18(11):1049-1060. PubMed ID: 28602103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects and Role of Multikinase Inhibitors in Thyroid Cancer.
    Laursen R; Wehland M; Kopp S; Pietsch J; Infanger M; Grosse J; Grimm D
    Curr Pharm Des; 2016; 22(39):5915-5926. PubMed ID: 27306093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic therapeutic approaches to advanced thyroid cancers.
    Menefee ME; Smallridge RC; Bible KC
    Am Soc Clin Oncol Educ Book; 2012; ():389-92. PubMed ID: 24451769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.